Your Gut Microbiome May Be Driving Dry Eye Disease
New review links gut dysbiosis, diet quality, and ocular microbiome disruption to dry eye disease progression and inflammation.
Summary
Dry eye disease (DED) affects hundreds of millions worldwide and is rising with age and screen time. This review reveals that nutrition and the gut-eye axis play underappreciated roles in DED. Omega-3 and omega-6 polyunsaturated fatty acids reduce ocular inflammation, while antioxidant-rich diets like the Mediterranean diet help stabilize the tear film. Conversely, food additives may worsen DED. Gut dysbiosis amplifies systemic inflammation, impairs immune regulation, and reduces short-chain fatty acids that protect mucosal surfaces including the eye. The ocular surface itself harbors a microbiome that defends against pathogens, and this is disturbed by aging, poor diet, and antibiotic overuse. Emerging interventions including probiotics, prebiotics, and fecal microbiota transplantation show early promise but need robust clinical validation.
Detailed Summary
Dry eye disease is one of the most prevalent age-related ocular conditions globally, causing chronic discomfort, visual disturbance, and reduced quality of life. Its incidence increases with aging, making it a legitimate healthspan concern — yet its nutritional and microbial underpinnings remain poorly recognized in clinical practice. This review synthesizes emerging evidence connecting diet, the gut microbiome, and the ocular surface microbiome to DED pathogenesis and management.
On the nutritional side, omega-3 and omega-6 polyunsaturated fatty acids exert anti-inflammatory effects that benefit the ocular surface, while dietary antioxidants — abundant in Mediterranean-style eating patterns — help stabilize the tear film and reduce oxidative stress. Food additives, by contrast, appear to have a detrimental effect on both systemic and ocular health, a finding relevant to the ultra-processed food landscape most aging populations navigate.
The review gives significant attention to the gut-eye axis: a bidirectional communication pathway through which gut dysbiosis can amplify systemic inflammation, disrupt immune homeostasis, and reduce production of short-chain fatty acids (SCFAs). SCFAs are critical anti-inflammatory metabolites with protective roles across mucosal tissues. An imbalanced gut microbiome thus sets conditions favorable for ocular surface inflammation and tear film instability.
The ocular surface itself hosts a distinct microbiome that helps maintain local immune defense and homeostasis. Aging, dietary shifts, and antibiotic exposure are identified as key factors eroding ocular microbial diversity. Microbiota-targeted interventions — probiotics, prebiotics, and fecal microbiota transplantation — are highlighted as promising but still early-stage strategies requiring well-controlled clinical trials.
The clinical implications are meaningful: dietary counseling (especially Mediterranean-pattern eating and omega-3 supplementation) and attention to gut health may constitute accessible adjuncts to conventional DED therapy. However, most supporting evidence is preclinical or from small preliminary studies, underscoring the need for randomized controlled trials before firm therapeutic recommendations can be made.
Key Findings
- Omega-3 and omega-6 fatty acids reduce ocular inflammation and may improve dry eye symptoms.
- Mediterranean diet antioxidants stabilize the tear film and lower oxidative stress in the eye.
- Gut dysbiosis depletes protective short-chain fatty acids, worsening systemic and ocular inflammation.
- Aging, antibiotics, and poor diet erode both gut and ocular surface microbial diversity.
- Probiotics, prebiotics, and fecal microbiota transplantation show early promise for dry eye but lack robust trial data.
Methodology
This is a narrative review published in a peer-reviewed Spanish ophthalmology journal, synthesizing existing preclinical and clinical literature on nutrition, gut-eye axis biology, and ocular surface microbiome in dry eye disease. No original experimental data were generated. The review draws primarily from preliminary clinical studies and animal model research, with no formal meta-analytic methodology described.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. The review itself acknowledges that current evidence is limited, largely preclinical, and insufficient to establish definitive clinical guidelines. No meta-analytic synthesis or formal quality assessment of included studies is described.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: